ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6.0 mg/ml - liraglutide - liraglutide - victoza is indicated for:• treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:1. as monotherapy when metformin is considered inappropriate due to intolerance or contraindications2. in addition to other medicinal products for the treatment of diabetes.• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6 mg / 1 ml - liraglutide - adultssaxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of •≥30 kg/m² (obesity), or •≥27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.adolescents (≥12 years)saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:• obesity (bmi corresponding to ≥30 kg/m2 for adults by international cut-off points)* and• body weight above 60 kg. treatment with saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their bmi or bmi z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. re-evaluation should be performed periodically

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 0.68 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 1.34 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 1.34 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 2.27 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 3.2 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - film coated tablets - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis. the experience treating women older than 65 years is limited.

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - film coated tablets - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered .the experience treating women older than 65 years is limited .

ইস্রায়েল - ইংরেজি - Ministry of Health

novo nordisk ltd., israel - insulin degludec; liraglutide - solution for injection - insulin degludec 100 u/ml; liraglutide 3.6 mg/ml - insulin degludec and liraglutide - xultophy® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control, and the population studied, see sections 4.4, 4.5 and 5.1